Division of Chiesi Farmaceutici SPA
Latest From CardioKine Inc.
Italian pharmaceutical company Chiesi is looking to buy up the remainder of Cornerstone Therapeutics, a company that already markets Chiesi’s products in the U.S. and is financially linked with the company.
Perhaps it was the fact that investors expected a US FDA rejection following the negative outcome of a September advisory committee meeting – or that Wall Street remained in shock, recovering from Hurricane Sandy – but shares of Cornerstone Therapeutics had only a somewhat mild reaction to regulators calling for more data before approving the company's experimental drug lixivaptan.
Shares of Cornerstone Therapeutics rose as high as 7% on 11 September after a US FDA drug reviewer said an argument could be made for approval of lixivaptan, an orally-active, selective vasopressin 2 receptor antagonist, as a treatment for hyponatremia associated with syndrome of inappropriate antidiuretic hormone secretion, or SIADH, based on the currently available information, as long as the therapy is restricted to inpatient initiation.
- Therapeutic Areas
- Metabolic Disorders
- North America
- Parent & Subsidiaries
- Chiesi Farmaceutici SPA
- Senior Management
Amber Salzman, PhD, Pres. & CEO
Mark Guerin, VP, Fin. & CFO
Cesare Orlandi, MD, SVP, Clinical Dev. & CMO
Len Selihar, VP, Alliance Mgmt. & Corp. Dev.
- Contact Info
Phone: (215) 399-1200
30 South 15th St.
Philadelphia, PA 19102
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.